Education
About Us
Working with TipRanks
Follow Us
Affluent Medical SA (DE:0JZ)
FRANKFURT:0JZ
0JZ Stock Chart & Stats
€3.51
-€0.04(-2.55%)
At close: 4:00 PM EST
€3.51
-€0.04(-2.55%)
Day’s Range― - ―
52-Week Range€1.23 - €3.95
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€213.19M
Enterprise Value€159.56M
Total Cash (Recent Filing)€5.35M
Total Debt (Recent Filing)€23.42M
Price to Earnings (P/E)―
Beta0.33
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding59,243,675
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.75
Price to Sales (P/S)12.90
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.80Price Target Upside8.26% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained >200% revenue growth indicates successful commercial traction and rapid market adoption of devices. Over a multi-month horizon this supports scale economics, broader clinical adoption and stronger negotiating power with hospitals and distributors, underpinning long-term expansion.
Improving Free Cash FlowMaterial FCF growth shows the business is improving cash generation despite losses. A positive FCF/net income ratio signals emerging cash stability that can fund operations, R&D, and commercialization with less external dilution, improving runway and strategic optionality over coming months.
Moderate Leverage / Balanced Capital StructureA moderate debt load and roughly 50% equity ratio provide financial flexibility for funding clinical trials and commercialization. This balanced capital structure reduces near-term refinancing risk and interest burden, supporting continued investment in product and market development.
Bears Say
Deep Negative ProfitabilitySeverely negative gross and net margins indicate core product economics are currently loss-making. Without durable margin improvement via pricing, cost reduction, or favorable product mix, the business will struggle to convert revenue growth into sustainable profits and fund long-term investments.
Poor Cash Conversion From OperationsNegative OCF-to-net-income shows reported earnings are not turning into operational cash, suggesting working capital drains or noncash accounting items. This weak cash conversion forces reliance on financing for growth and raises execution risk for commercialization and regulatory milestones.
Negative Return On EquityA deep negative ROE implies the company is destroying shareholder capital rather than generating returns. Persistently negative ROE undermines investor confidence, can limit access to attractive financing, and constrains the firm’s ability to invest competitively in R&D and market expansion.
Affluent Medical SA News
0JZ FAQ
What was Affluent Medical SA’s price range in the past 12 months?
Affluent Medical SA lowest stock price was €1.23 and its highest was €3.95 in the past 12 months.
What is Affluent Medical SA’s market cap?
Affluent Medical SA’s market cap is €213.19M.
When is Affluent Medical SA’s upcoming earnings report date?
Affluent Medical SA’s upcoming earnings report date is Apr 23, 2026 which is in 65 days.
How were Affluent Medical SA’s earnings last quarter?
Affluent Medical SA released its earnings results on Sep 25, 2025. The company reported -€0.238 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.238.
Is Affluent Medical SA overvalued?
According to Wall Street analysts Affluent Medical SA’s price is currently Undervalued.
Does Affluent Medical SA pay dividends?
Affluent Medical SA does not currently pay dividends.
What is Affluent Medical SA’s EPS estimate?
Affluent Medical SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Affluent Medical SA have?
Affluent Medical SA has 59,243,675 shares outstanding.
What happened to Affluent Medical SA’s price movement after its last earnings report?
Affluent Medical SA reported an EPS of -€0.238 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.98%.
Which hedge fund is a major shareholder of Affluent Medical SA?
Currently, no hedge funds are holding shares in DE:0JZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Affluent Medical SA
Affluent Medical SA develops minimally invasive medical devices for the treatment of heart and vascular diseases in France. It develops Kardiozis technology for the treatment of abdominal aortic aneurysm; Kalios and Epygon implants to treat mitral insufficiency; and Artus implant, an implantable electro-mechanical artificial sphincter for the treatment of severe urinary incontinence in women and men. The company was founded in 2011 and is based in Aix-en-Provence, France.
0JZ Stock 12 Month Forecast
Average Price Target
€3.80
▲(8.26% Upside)
Technical Analysis
Carmat SA
―
Theraclion SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―
Median Technologies
―